ASX · M7T.AX
Mach7 Technologies Limited
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
Loading market information…
ASX · CMP.AX · AUD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 01:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Compumedics Limited’s quoted price sits in the lower half of its reported 52-week range, 48.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Compumedics Limited’s next earnings report is currently expected on Mar 4, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Compumedics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.44+A$0.05 (+12.99%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 66.28% below the high.
A$0.09-A$0.00 (-2.25%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.36% below the high.
A$0.47A$0.00 (0.0%)
CleanSpace Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
A$0.10-A$0.01 (-4.76%)
Doctor Care Anywhere Group PLC’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
A$0.04-A$0.00 (-5.13%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
A$0.07A$0.00 (0.0%)
Beamtree Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 68.44% below the high.
A$0.08-A$0.00 (-3.8%)
Genetic Signatures Limited’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
